Alpha-GPC vs NSI-189

Mechanism

Highly bioavailable choline source that crosses the blood-brain barrier efficiently via passive diffusion. Serves as a direct precursor for acetylcholine synthesis and phosphatidylcholine, a major structural component of neuronal membranes. Also stimulates growth hormone release via cholinergic activation of GHRH-releasing neurons in the hypothalamus. Contains ~40% choline by weight.

Standard Dosing

300-600 mg/day

Timing

Morning or pre-workout. Can be taken with or without food. Split into 1-2 doses.

Cycle Duration

Ongoing; no cycling required for standard doses

Side Effects

• GI distress
• Headache
• Dizziness
• Fishy body odor at high doses
• Potential TMAO elevation with chronic high-dose use

Contraindications

• Active peptic ulcer disease
• TMAO concerns — emerging research links high choline intake to elevated TMAO and cardiovascular risk

Best Stacking Partners

Mechanism

Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.

Standard Dosing

40 mg once daily (for educational context — investigational compound, not approved for any indication)

Timing

Once daily, time of day not definitively established from clinical data. With or without food.

Cycle Duration

Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.

Side Effects

• Headache
• GI discomfort
• Dizziness
• Somnolence
• Dry mouth
• Generally well-tolerated in Phase 1b and Phase 2 trials

Contraindications

• Pregnancy and lactation (no safety data; neurogenic compounds carry theoretical teratogenic risk)
• History of brain tumors (neurogenic stimulation could theoretically promote growth — speculative)
• No regulatory approval for any indication — investigational use only

Best Stacking Partners